Single dose mizoribine treatment for RA: Clinical study from patient with complications and/or drug-refractory stage

Abstract

    We performed single dose mizoribine (MZR: immunosuppressive drug) treatment with high daily concentration for patients with rheumatoid arthritis (RA). This clinical trial was performed on 18 RA patients (4 Male, 14 Female. Age 33-81. Duration 1-15 years. StageI: 5, III: 1, IV: 12. Class2: 13, 3: 4. Disease Activity Score: DAS 28＝5.0＋/－1.3) with complications and/or some drugs refractory stage in Kinki University School of Medicine over six months. Finally, five of the 18 RA patients improved in not only clinical data on the DAS 28＝3.7＋/－0.9 and personal comfortableness but also decreased steroid dose and other drugs. Another five RA patients continued the trial but remained unchanged (DAS 28＝4.3＋/－1.0), and eight RA patients discontinued the trial: three were unchanged (DAS 28＝5.1＋/－0.7), three were personal dropout (DAS 28＝6.1＋/－1.0), one was side effect (oral erosion on 3 months later) and one was worse. Five of the eight dropout RA patients used biologics after this trail. The effectiveness of single dose mizoribin treatment for RA patients was demonstrated one of the effectiveness in this study.